Clinical assessment of lurasidone benefit and risk in the treatment of bipolar i depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed

Journal of Affective Disorders

Volumn 155, Issue 1, 2014, Pages 20-27

  Citrome, Leslie ^a   Ketter, Terence A ^b   Cucchiaro, Josephine ^c   Loebel, Antony ^c  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Bipolar I depression; Efficacy; Lurasidone; Number needed to harm; Number needed to treat; Tolerability

Indexed keywords

GLUCOSE; LITHIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LURASIDONE; TRIACYLGLYCEROL; VALPROIC ACID;

ADULT; AKATHISIA; BIPOLAR DEPRESSION; BIPOLAR I DEPRESSION; BIPOLAR I DISORDER; BODY WEIGHT DISORDER; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSOMNIA; LIKELIHOOD OF BEING HELPED OR HARMED; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; NUMBERS NEEDED TO HARM; NUMBERS NEEDED TO TREAT; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SOMNOLENCE; STATISTICAL ANALYSIS; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

BIPOLAR I DEPRESSION; EFFICACY; LURASIDONE; NUMBER NEEDED TO HARM; NUMBER NEEDED TO TREAT; TOLERABILITY;

ANTIMANIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; ISOINDOLES; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; THIAZOLES; TREATMENT OUTCOME;

EID: 84891867256     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2013.10.040     Document Type: Review

References (26)

1. AstraZeneca, 2011a. Seroquel (quetiapine fumarate). Revised December 2011. Available from: http://www1.astrazeneca-us.com/pi/Seroquel.pdf accessed 28.01.13.
2. AstraZeneca, 2011b. Seroquel XR (quetiapine fumarate extended release). Revised December 2011. Available from: http://www1.astrazeneca-us.com/pi/ seroquelxr.pdf accessed 28.01.13.
3. J.R. Calabrese, P.E. Keck Jr., W. Macfadden, M. Minkwitz, T.A. Ketter, R.H. Weisler, A.J. Cutler, R. McCoy, E. Wilson, and J. Mullen A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression Am. J. Psychiatry 162 2005 1351 1360
4. L. Citrome Compelling or irrelevant? Using number needed to treat can help decide Acta Psychiatr. Scand. 117 2008 412 419
5. L. Citrome, and J. Kantrowitz Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks Expert Rev. Neurother. 8 2008 1079 1091
6. L. Citrome Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications Curr. Drug Saf. 4 2009 229 237
7. L. Citrome Relative vs. absolute measures of benefit and risk: what is the difference? Acta Psychiatr. Scand. 121 2010 94 102
8. L. Citrome Olanzapine-fluoxetine combination for the treatment of bipolar depression Expert Opin. Pharmacother. 12 2011 2751 2758
9. L. Citrome Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic Int. J. Clin. Pract. 65 2011 189 210
10. L. Citrome Number needed to treat: what it is and what it is not, and why every clinician should know how to calculate it J. Clin. Psychiatry 72 2011 412 413
11. L. Citrome, R.I. Holt, D.J. Walker, and V.P. Hoffmann Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder Clin. Drug Investig. 31 2011 455 482
12. L. Citrome Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Clin. Schizophr. Relat. Psychoses 6 2012 76 85
13. L. Citrome, and T.A. Ketter When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed Int. J. Clin. Pract. 67 2013 407 411
14. L. Citrome, J.F. Goldberg, and K.B. Portland Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed J. Affect. Disord. 151 2013 409 417
15. Eli Lilly, 2013. Symbyax (olanzapine and fluoxetine hydrochloride). Revised January 2013. Available from: http://pi.lilly.com/us/symbyax-pi.pdf accessed 28.01.13.
16. T.A. Ketter Handbook of Diagnosis and Treatment of Bipolar Disorder 2010 American Psychiatric Publishing, Inc. Washington, DC
17. T.A. Ketter, L. Citrome, P.W. Wang, J.L. Culver, and S. Srivastava Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? Acta Psychiatr. Scand. 123 2011 175 189
18. A. Loebel, J. Cucchiaro, R. Silva, H. Kroger, K. Sarma, J. Xu, and J.R. Calabrese Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study Am. J. Psychiatry 2013 (in press)
19. A. Loebel, J. Cucchiaro, R. Silva, H. Kroger, J. Hsu, K. Sarma, and G. Sachs Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study Am. J. Psychiatry 2013 (in press)
20. I. Lombardo, G. Sachs, S. Kolluri, C. Kremer, and R. Yang Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J. Clin. Psychopharmacol. 32 2012 470 478
21. M.M. Sidor, and G.M. Macqueen Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis J. Clin. Psychiatry 72 2011 156 167
22. S.E. Straus Individualizing treatment decisions. The likelihood of being helped or harmed Eval. Health Prof. 25 2002 210 224
23. Sunovion, 2013. Latuda (lurasidone). Revised July 2013. Available from: http://www.latuda.com/LatudaPrescribingInformation.pdf accessed 07.08.13.
24. T. Suppes, C. Datto, M. Minkwitz, A. Nordenhem, C. Walker, and D. Darko Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression J. Affect. Disord. 121 2010 106 115
25. M.E. Thase, W. Macfadden, R.H. Weisler, W. Chang, B. Paulsson, A. Khan, J.R. Calabrese BOLDER II Study Group Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study) J. Clin. Psychopharmacol. 26 2006 600 609
26. M. Tohen, E. Vieta, J. Calabrese, T.A. Ketter, G. Sachs, C. Bowden, P.B. Mitchell, F. Centorrino, R. Risser, R.W. Baker, A.R. Evans, K. Beymer, S. Dube, G.D. Tollefson, and A. Breier Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression Arch. Gen. Psychiatry 60 2003 1079 1088